RXRX FY 2025 Earnings — Recursion Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RXRXRecursion Pharmaceuticals, Inc.

$2B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$75M+26.9% YoY

Gross Profit

-$46M-62.0% margin

Operating Income

-$648M-867.9% margin

Net Income

-$645M-863.4% margin

EPS (Diluted)

$-1.44

Cash Flow

Operating Cash Flow

-$372M

Free Cash Flow

-$378M

Stock-Based Comp.

$111M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$343M

Stockholders' Equity

$1.1B

Cash & Equivalents

$743M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$75M	$59M	+26.9%
Gross Profit	-$46M	$14M	-440.2%
Operating Income	-$648M	-$479M	-35.3%
Net Income	-$645M	-$464M	-39.1%